NuCana (NCNA) Competitors $5.64 -0.14 (-2.34%) As of 01:14 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NCNA vs. BPTH, BON, VINC, SYRS, PBLA, VRPX, SMFL, NKGN, SCPS, and VAXXShould you be buying NuCana stock or one of its competitors? The main competitors of NuCana include Bio-Path (BPTH), Bon Natural Life (BON), Vincerx Pharma (VINC), Syros Pharmaceuticals (SYRS), Panbela Therapeutics (PBLA), Virpax Pharmaceuticals (VRPX), Smart for Life (SMFL), NKGen Biotech (NKGN), Scopus BioPharma (SCPS), and Vaxxinity (VAXX). These companies are all part of the "pharmaceutical products" industry. NuCana vs. Its Competitors Bio-Path Bon Natural Life Vincerx Pharma Syros Pharmaceuticals Panbela Therapeutics Virpax Pharmaceuticals Smart for Life NKGen Biotech Scopus BioPharma Vaxxinity Bio-Path (NASDAQ:BPTH) and NuCana (NASDAQ:NCNA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation. Do analysts prefer BPTH or NCNA? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has better valuation & earnings, BPTH or NCNA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBio-PathN/AN/A-$16.08MN/AN/ANuCanaN/AN/A-$24.28M-$646.16-0.01 Does the media favor BPTH or NCNA? In the previous week, NuCana had 2 more articles in the media than Bio-Path. MarketBeat recorded 2 mentions for NuCana and 0 mentions for Bio-Path. NuCana's average media sentiment score of 0.95 beat Bio-Path's score of 0.00 indicating that NuCana is being referred to more favorably in the news media. Company Overall Sentiment Bio-Path Neutral NuCana Positive Is BPTH or NCNA more profitable? NuCana's return on equity of -592.28% beat Bio-Path's return on equity.Company Net Margins Return on Equity Return on Assets Bio-PathN/A -2,842.40% -337.48% NuCana N/A -592.28%-208.68% Which has more volatility and risk, BPTH or NCNA? Bio-Path has a beta of -0.08, meaning that its stock price is 108% less volatile than the S&P 500. Comparatively, NuCana has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500. Do institutionals and insiders have more ownership in BPTH or NCNA? 5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 44.0% of NuCana shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by insiders. Comparatively, 31.2% of NuCana shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryNuCana beats Bio-Path on 8 of the 9 factors compared between the two stocks. Get NuCana News Delivered to You Automatically Sign up to receive the latest news and ratings for NCNA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NCNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NCNA vs. The Competition Export to ExcelMetricNuCanaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$165K$3.36B$6.03B$10.48BDividend YieldN/A2.31%5.73%4.82%P/E Ratio-0.0122.0685.4727.11Price / SalesN/A466.79594.15131.81Price / CashN/A44.9825.7730.18Price / Book0.0210.3912.506.70Net Income-$24.28M-$52.47M$3.32B$276.55M7 Day Performance-21.51%-0.15%-0.22%-0.02%1 Month Performance42.75%13.41%8.50%7.10%1 Year Performance-98.57%19.89%75.45%41.82% NuCana Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NCNANuCana1.3669 of 5 stars$5.65-2.3%N/A-98.6%$169KN/A-0.0130BPTHBio-Path0.8818 of 5 stars$0.06-1.6%N/A-94.0%$564KN/A0.0010Gap DownBONBon Natural Life0.6855 of 5 stars$2.07+0.9%N/AN/A$351K$23.84M0.00100Gap UpVINCVincerx Pharma0.5197 of 5 stars$0.05-1.9%$40.00+78,331.4%-99.5%$267KN/A0.0060Negative NewsGap DownSYRSSyros Pharmaceuticals3.7956 of 5 stars$0.01+4,900.0%$1.00+19,900.0%-99.7%$134K$386K0.00120Gap UpPBLAPanbela Therapeutics0.0894 of 5 stars$0.01+0.9%N/A-96.9%$54KN/A0.006VRPXVirpax Pharmaceuticals0.0523 of 5 stars$0.02+90.9%N/A-99.8%$26KN/A0.007Gap UpSMFLSmart for LifeN/A$0.00-66.7%N/A-93.7%$14K$11.11M0.00110Gap DownNKGNNKGen Biotech0.1374 of 5 stars$0.00+50.0%N/A-96.4%$13KN/A0.00N/AGap UpSCPSScopus BioPharmaN/A$0.00flatN/AN/A$13KN/A0.009VAXXVaxxinityN/A$0.00-99.0%N/A-97.5%$13KN/A0.0090Gap Down Related Companies and Tools Related Companies Bio-Path Competitors Bon Natural Life Competitors Vincerx Pharma Competitors Syros Pharmaceuticals Competitors Panbela Therapeutics Competitors Virpax Pharmaceuticals Competitors Smart for Life Competitors NKGen Biotech Competitors Scopus BioPharma Competitors Vaxxinity Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NCNA) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersThe Army Just Got a New Drone SupplierA cutting-edge drone developer just secured a U.S. Army deal to supply its Flex FPV Modular Drones and build a...The Tomorrow Investor | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NuCana PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share NuCana With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
